Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications

Proteomics

Volumn 10, Issue 24, 2010, Pages 4415-4430

  Ling, Xuefeng B ^a   Park, Jane L ^a   Carroll, Tanya ^a   Nguyen, Khoa D ^a   Lau, Kenneth ^a   Macaubas, Claudia ^a   Chen, Edward ^a   Lee, Tzielan ^a   Sandborg, Christy ^a   Milojevic, Diana ^b   Kanegaye, John T ^c   Gao, Susanna ^a   Burns, Jane ^d   Schilling, James ^a   Mellins, Elizabeth D ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

2 D DIGE; Kawasaki disease; MALDI TOF TOF MS; Systemic juvenile idiopathic arthritis; Systems biology

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN D; APOLIPOPROTEIN E; C REACTIVE PROTEIN; CALGRANULIN A; CALGRANULIN B; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C9; COMPLEMENT FACTOR H; GELSOLIN; HEMOGLOBIN; INTER ALPHA TRYPSIN INHIBITOR; OROSOMUCOID; PLASMA KALLIKREIN; PLASMA PROTEIN; PREALBUMIN; VITAMIN D BINDING PROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HUMAN CELL; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION STUDY;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFANT; YOUNG ADULT;

EID: 78649709787     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000298     Document Type: Article

References (69)

1. Weiss, J. E., Ilowite, N. T., Juvenile idiopathic arthritis. Pediatr. Clin. North Am. 2005, 52, 413-442, vi.
2. Singh-Grewal, D., Schneider, R., Bayer, N., Feldman, B. M., Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum. 2006, 54, 1595-1601.
3. Vastert, S. J., Kuis, W., Grom, A. A., Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract. Res. Clin. Rheumatol. 2009, 23, 655-664.
4. Schneider, R., Laxer, R. M., Systemic onset juvenile rheumatoid arthritis. Baillieres Clin. Rheumatol. 1998, 12, 245-271.
5. Wallace, C. A., Levinson, J. E., Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum. Dis. Clin. North Am. 1991, 17, 891-905.
6. Lomater, C., Gerloni, V., Gattinara, M., Mazzotti, J. et al., Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 2000, 27, 491-496.
7. Calabro, J. J., Holgerson, W. B., Sonpal, G. M., Khoury, M. I., Juvenile rheumatoid arthritis: a general review and report of 100 patients observed for 15 years. Semin. Arthritis Rheum. 1976, 5, 257-298.
8. Mottonen, T., Hannonen, P., Leirisalo-Repo, M., Nissila, M. et al., Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999, 353, 1568-1573.
9. Foell, D., Wittkowski, H., Hammerschmidt, I., Wulffraat, N. et al., Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum. 2004, 50, 1286-1295.
10. Wittkowski, H., Frosch, M., Wulffraat, N., Goldbach-Mansky, R. et al., S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum. 2008, 58, 3924-3931.
11. Wittkowski, H., Hirono, K., Ichida, F., Vogl, T. et al., Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum. 2007, 56, 4174-4181.
12. Frosch, M., Vogl, T., Seeliger, S., Wulffraat, N. et al., Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2003, 48, 2622-2626.
13. Frosch, M., Ahlmann, M., Vogl, T., Wittkowski, H. et al., The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009, 60, 883-891.
14. de Jager, W., Hoppenreijs, E. P., Wulffraat, N. M., Wedderburn, L. R. et al., Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann. Rheum. Dis. 2007, 66, 589-598.
15. Jelusic, M., Lukic, I. K., Tambic-Bukovac, L., Dubravcic, K. et al., Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. Clin. Rheumatol. 2007, 26, 1332-1334.
16. Miyamae, T., Malehorn, D., Lemster, B., Mori, M. et al., Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy. Arthritis Res. Ther. 2005, 7, R746-R755.
17. Sobieska, M., Fassbender, K., Aeschlimann, A., Bourgeois, P. et al., Still's disease in children and adults: a distinct pattern of acute-phase proteins. Clin. Rheumatol. 1998, 17, 258-260.
18. Chen, D. Y., Chen, Y. M., Ho, W. L., Chen, H. H. et al., Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still's disease. Ann. Rheum. Dis. 2009, 68, 1074-1075.
19. Eberhard, O. K., Haubitz, M., Brunkhorst, F. M., Kliem, V. et al., Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997, 40, 1250-1256.
20. Delevaux, I., Andre, M., Colombier, M., Albuisson, E. et al., Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann. Rheum. Dis. 2003, 62, 337-340.
21. Burns, J. C., Glode, M. P., Kawasaki syndrome. Lancet 2004, 364, 533-544.
22. Petty, R., Southwood, T., Manners, P., Baum, J. et al., International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004, 31, 390-392.
23. Sandborg, C., Holmes, T., Lee, T., Biederman, K. et al., Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J. Rheumatol. 2006, 33, 2322-2329.
24. Efron, B., Tibshirani, R., Storey, J., Tusher, V., Empirical bayes analysis of microarray experiment. J. Am. Stat. Assoc. 2001, 96, 1151-1160.
25. Tibshirani, R., Hastie, T., Narasimhan, B., Chu, G., Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. USA 2002, 99, 6567-6572.
26. Zweig, M. H., Campbell, G., Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 1993, 39, 561-577.
27. Sing, T., Sander, O., Beerenwinkel, N., Lengauer, T., ROCR: visualizing classifier performance in R. Bioinformatics 2005, 21, 3940-3941.
28. Jacobs, J. M., Adkins, J. N., Qian, W. J., Liu, T. et al., Utilizing human blood plasma for proteomic biomarker discovery. J. Proteome Res. 2005, 4, 1073-1085.
29. Roche, S., Tiers, L., Provansal, M., Seveno, M. et al., Depletion of one, six, twelve or twenty major blood proteins before proteomic analysis: the more the better? J. Proteomics 2009, 72, 945-951.
30. Tibshirani, R., Hastie, T., Narasimhan, B., Chu, G., Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. USA 2002, 99, 6567-6572.
31. Huang, H.-L., Stasyk, T., Morandell, S., Mogg, M. et al., Enrichment of low-abundant serum proteins by albumin/immunoglobulin G immunoaffinity depletion under partly denaturing conditions. Electrophoresis 2005, 26, 2843-2849.
32. Gibson, D. S., Blelock, S., Curry, J., Finnegan, S. et al., Comparative analysis of synovial fluid and plasma proteomes in juvenile arthritis - proteomic patterns of joint inflammation in early stage disease. J. Proteomics 2009, 72, 656-676.
33. Anderson, N., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
34. Tirumalai, R. S., Chan, K. C., Prieto, D. A., Issaq, H. J. et al., Characterization of the low molecular weight human serum proteome. Mol. Cell. Proteomics 2003, 2, 1096-1103.
35. De Beer, F. C., Mallya, R. K., Fagan, E. A., Lanham, J. G. et al., Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982, 2, 231-234.
36. Wu, J. F., Yang, Y. H., Wang, L. C., Lee, J. H. et al., Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in juvenile rheumatoid arthritis. Clin.Exp. Rheumatol. 2007, 25, 782-785.
37. Tselepis, A. D., Elisaf, M., Besis, S., Karabina, S. A. et al., Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity. Arthritis Rheum. 1999, 42, 373-383.
38. Black, S., Kushner, I., Samols, D., C-reactive protein. J. Biol. Chem. 2004, 279, 48487-48490.
39. Dayer, E., Dayer, J.-M., Roux-Lombard, P., Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases. Nat. Rev. Rheumatol. 2007, 3, 512-520.
40. Armstrong, P. B., Quigley, J. P., Alpha2-macroglobulin: an evolutionarily conserved arm of the innate immune system. Dev. Comp. Immunol. 1999, 23, 375-390.
41. Yui, Y., Aoyama, T., Morishita, H., Takahashi, M. et al., Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. J. Clin. Invest. 1988, 82, 803-807.
42. Navab, M., Anantharamaiah, G. M., Fogelman, A., The role of high-density lipoprotein in inflammation. Trends Cardiovasc. Med. 2005, 15, 158-161.
43. Khovidhunkit, W., Duchateau, P., Medzihradszky, K., Moser, A. et al., Apolipoproteins A-IV and A-V are acute-phase proteins in mouse HDL. Atherosclerosis 2004, 176, 37-44.
44. Recalde, D., Ostos, M. A., Badell, E., Garcia-Otin, A. L. et al., Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 756-761.
45. Braunwald, E., Biomarkers in heart failure. N. Engl. J. Med. 2008, 358, 2148-2159.
46. Kawachi-Takahashi, S., Tanaka, K., Takahashi, M., Kawashima, T., Shimada, K., Determination of serum C9 level by immunodiffusion. Elevation in patients with infectious or allergic skin diseases. Int. Arch. Allergy Appl. Immunol. 1975, 48, 161-170.
47. Kawachi-Takahashi, S., Takahashi, M., Kogure, M., Kawashima, T., Letter: elevation of serum C9 level associated with Behcet disease. Jpn J. Exp. Med. 1974, 44, 845-847.
48. Bene, L., Fust, G., Fekete, B., Kovacs, A. et al., High normal serum levels of C3 and C1 inhibitor, two acute-phase proteins belonging to the complement system, occur more frequently in patients with Crohn's disease than ulcerative colitis. Dig. Dis. Sci. 2003, 48, 1186-1192.
49. Yu, H.-R., Kuo, H.-C., Sheen, J.-M., Wang, L. et al., A unique plasma proteomic profiling with imbalanced fibrinogen cascade in patients with Kawasaki disease. Pediatr. Allergy Immunol. 2009, 20, 699-707.
50. Ogilvie, E., Khan, A., Hubank, M., Kellam, P., Woo, P., Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheumat. 2007, 56, 1954-1965.
51. Gabay, C., Kushner, I., Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999, 340, 448-454.
52. Pascual, V., Allantaz, F., Arce, E., Punaro, M., Banchereau, J., Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 2005, 201, 1479-1486.
53. Yokota, S., Imagawa, T., Mori, M., Miyamae, T. et al., Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371, 998-1006.
54. Prince, F. H., Twilt, M., Ten Cate, R., Van Rossum, M. A. et al., Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann. Rheum. Dis. 2009, 68, 635-641.
55. Pascual, V., Farkas, L., Banchereau, J., Systemic lupus erythematosus: all roads lead to type I interferons. Curr. Opin. Immunol. 2006, 18, 676-682.
56. Wilson, D. C., Marinov, A. D., Blair, H. C., Bushnell, D. S. et al., Follistatin-like-protein-1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2010, 162, 2510-2516.
57. Fall, N., Barnes, M., Thornton, S., Luyrink, L. et al., Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 2007, 56, 3793-3804.
58. Wu, W., Wang, G., Baek, S., Shen, R.-F., Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J. Proteome Res. 2006, 5, 651-658.
59. Ge, X., Ma, X., Meng, J., Zhang, C. et al., Role of Wnt-5A in interleukin-1beta-induced matrix metalloproteinase expression in rabbit temporomandibular joint condylar chondrocytes. Arthritis Rheum. 2009, 60, 2714-2722.
60. Lin, C.-C., Kuo, C.-T., Cheng, C.-Y., Wu, C.-Y. et al., IL-1 beta promotes A549 cell migration via MAPKs/AP-1- and NF-kappaB-dependent matrix metalloproteinase-9 expression. Cell. Signal. 2009, 21, 1652-1662.
61. Migita, K., Yamasaki, S., Shibatomi, K., Ida, H. et al., Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes. Clin. Exp. Immunol. 2001, 123, 408-411.
62. Hyka, N., Dayer, J. M., Modoux, C., Kohno, T. et al., Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001, 97, 2381-2389.
63. Foell, D., Wulffraat, N., Wedderburn, L. R., Wittkowski, H. et al., Methotrexate withdrawal at 6 versus 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. J Am Med Assoc 2010, 303, 1266-1273.
64. Schulze zur Wiesch, A., Foell, D., Frosch, M., Vogl, T. et al., Myeloid related proteins MRP8/MRP14 may predict disease flares in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2004, 22, 368-373.
65. Sandborg, C., Holmes, T. H., Lee, T., Biederman, K. et al., Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J. Rheumatol. 2006, 33, 2322-2329.
66. Wallace, C., Huang, B., Bandeira, M., Ravelli, A., Giannini, E., Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheumat. 2005, 52, 3554-3562.
67. Gattorno, M., Piccini, A., Lasiglie, D., Tassi, S. et al., The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheumat. 2008, 58, 1505-1515.
68. Woo, P., Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat. Clin. Prac. Rheumatol. 2006, 2, 28-34.
69. Sawhney, S., Woo, P., Murray, K. J., Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch. Dis. Childhood 2001, 85, 421-426.